Physician profile
Chiwai E Chan
NPI 1629051529
$666.81
in general payments reported to CMS, 2019-2025
15 companies · $27.46 in 2025
The $27.46 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $55.20 · 2024: $112 · 2025: $27.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $139.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $185.15 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Daiichi Sankyo INC. | $69.08 | 2019 | |
| Pfizer INC. | $64.55 | 2019 | |
| Novartis Pharmaceuticals Corporation | $60.72 | 2019 | |
| Abbvie INC. | $57.47 | 2024-2025 | |
| Scilex Pharmaceuticals INC. | $54.32 | 2019-2024 | |
| Amgen INC. | $32.59 | 2019 | |
| Valinor Pharma, LLC | $29.05 | 2024 | Movantik |
| Medtronic USA, INC. | $21.27 | 2019 | |
| Abbott Laboratories | $19.34 | 2019 | |
| Nevro Corp. | $17.75 | 2019 | |
| Allergan, INC. | $15.77 | 2019 | |
| Assertio Therapeutics, INC. | $15.29 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.78 | 2019 | |
| Sentynl Therapeutics, INC. | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chiwai Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.